SciRhom

Scirhom is a biotechnology company focused on developing innovative therapies targeting iRhom2, an inactive rhomboid protease. The company aims to address unmet medical needs in the fields of immunology, inflammation, oncology, infectious, and metabolic diseases. By inhibiting iRhom2, Scirhom seeks to selectively target the pro-inflammatory functions of TACE (Tumor Necrosis Factor-Alpha Converting Enzyme) without causing the severe side effects associated with direct TACE inhibition. This approach offers a promising alternative for treating conditions such as rheumatoid arthritis, hemophilia-induced inflammatory arthritis, and systemic lupus erythematosus. Scirhom's business model revolves around research and development, with a focus on preclinical and clinical trials to validate the efficacy and safety of their iRhom2 inhibitors. The company generates revenue through partnerships, licensing agreements, and potential future sales of approved therapies. Scirhom serves pharmaceutical companies, healthcare providers, and patients seeking advanced treatments for chronic inflammatory and autoimmune diseases.

Keywords: iRhom2 inhibitors, TACE, inflammation, autoimmune diseases, rheumatoid arthritis, hemophilia, lupus, oncology, biotechnology, therapeutic development.